Drug
Dabrafenib clinical trials
Also written GSK2118436 and GSK-2118436A.
Includes 10 studies of Dabrafenib mesylate.
- studies test it
- 106
- open now
- 18
- in phase 3
- 9
- first study started
- 2010
Keep track of what changes. Save the dabrafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
106 studies that test it; most in 2013 (13)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 13 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 10 |
| 2018 | 9 |
| 2019 | 5 |
| 2020 | 9 |
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 42
- Phase 2
- 64
- Phase 3
- 9
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 45
Who runs them
Industry 38 · Other 68
Novartis Pharmaceuticals (17) · GlaxoSmithKline (13) · National Cancer Institute (NCI) (12) · M.D. Anderson Cancer Center (5) · Massachusetts General Hospital (4) · Melanoma Institute Australia (2) · Memorial Sloan Kettering Cancer Center (2) · University of California, San Francisco (2)
Often tested with
Tested in the same studies.
Trametinib (62) · Pembrolizumab (10) · Nivolumab (8) · Palbociclib (6) · Olaparib (6) · Vemurafenib (6) · Afatinib (4) · Binimetinib (4)
Studies
Open first, then newest update. How each study uses dabrafenib is read from its arms, and is right about nine times in ten.
Testing it · 106
- Dabrafenib and/or Trametinib Rollover StudyRecruitingPhase 4Novartis PharmaceuticalsNCT03340506Written as dabrafenib
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingPhase 2University of California, San FranciscoNCT07110246Written as Dabrafenib
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07886905Written as Dabrafenib
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT07440290Written as Dabrafenib
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingPhase 1/2Ann & Robert H Lurie Children's Hospital of ChicagoNCT06712875Written as Dabrafenib, trametinib, nivolumab
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Dabrafenib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Dabrafenib+Trametinib
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07506109Written as Dabrafenib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Dabrafenib
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as Dabrafenib
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingPhase 2Tianjin Medical University Second HospitalNCT06739395Written as Dabrafenib
- Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT06653517Written as Dabrafenib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Dabrafenib
- Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNot yet recruitingPhase 3Shandong UniversityNCT06264778Written as Dabrafenib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Dabrafenib
- Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsRecruitingPhase 2Se Jun ParkNCT05876806Written as Dabrafenib
- A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05182931Written as Dabrafenib 75 MG
- Melanoma Metastasized to the Brain and SteroidsRecruitingPhase 2Inge Marie SvaneNCT03563729Written as Dabrafenib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Dabrafenib
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02196181Written as Dabrafenib Mesylate
See all 106 studies that test dabrafenib →
Given in every arm · 21 — dabrafenib is usual care beside what is tested
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Dabrafenib
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04527549Written as Dabrafenib mesylate
- PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04544111Written as Dabrafenib
- Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingPhase 2Massachusetts General HospitalNCT03149029Written as Dabrafenib
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01989585Written as Dabrafenib
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedPhase 1Novartis PharmaceuticalsNCT04294160Written as Dabrafenib
- A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedPhase 3Novartis PharmaceuticalsNCT02967692Written as Dabrafenib
- Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid CancerCompletedPhase 2Bhavana KondaNCT01723202Written as dabrafenib
- Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03026517Written as Dabrafenib
- MCS110 With BRAF/MEK Inhibition in Patients With MelanomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT03455764Written as Dabrafenib
- TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaCompletedPhase 2Universitair Ziekenhuis BrusselNCT04059224Written as Dabrafenib
- Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.CompletedPhase 2Novartis PharmaceuticalsNCT01336634Written as Dabrafenib
- Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedPhase 1/2Abramson Cancer Center at Penn MedicineNCT02257424Written as dabrafenib 150 mg orally twice a day
- A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaCompletedPhase 3Novartis PharmaceuticalsNCT01584648Written as Dabrafenib
- Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnPhase 2TriHealth Inc.NCT03972046Written as Dabrafenib (BRAF Inhibitor)
- Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212CompletedPhase 2Novartis PharmaceuticalsNCT01072175Written as GSK2118436
- A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01231594Written as GSK2118436
- Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and MetabolitesTerminatedPhase 2GlaxoSmithKlineNCT01978236Written as Dabrafenib 150 mg
- Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaCompletedPhase 1GlaxoSmithKlineNCT01767454Written as Dabrafenib
- A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid TumorsCompletedPhase 1GlaxoSmithKlineNCT00880321Written as GSK2118436
Showing 20 of 21.
As the comparator · 1 — what is tested is compared with dabrafenib
Codes
What other systems call dabrafenib · ClinicalTrials.gg INT005899
- MeSH (NLM) C561627dabrafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QGP4HA4G1BDABRAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 1424911Confirmed FDA, Wikidata
- Wikidata Q3011604dabrafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82386DabrafenibOne source FDA
- DrugBank DB08912One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C561627 | dabrafenib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QGP4HA4G1B | DABRAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1424911 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3011604 | dabrafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82386 | Dabrafenib | One source FDA |
| DrugBank | DB08912 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.